Non-intoxicating cannabinoids are moving into food, beverage, and dietary-supplement formulations, placing food-safety, regulatory, and quality teams at the center of ingredient and supplier approval. This panel brings together a cannabinoid ingredient manufacturer built for institutional scrutiny with food-safety auditors, regulatory and GRAS experts, and CPG and supplement quality leaders responsible for evaluating ingredient suppliers. Together, the panel will examine two related questions. First, what does it take for a cannabinoid supplier to meet the safety, quality, and documentation standards expected of a mainstream food or dietary-ingredient supplier? Second, do the existing GRAS and New Dietary Ingredient processes provide a sufficient framework for evaluating non-intoxicating cannabinoids, or are additional clarity, evidence, or regulatory guidance needed? The discussion will explore how GFSI-aligned systems, HACCP and preventive controls, third-party supplier audits, GRAS conclusions, and NDI notifications apply in practice. Panelists will consider what evidence should support ingredient approval, including validated manufacturing processes, specifications, identity and potency testing, contaminant controls, stability, traceability, GLP toxicology, human safety data, and conditions of intended use. Attendees will leave with a practical view of cannabinoid supplier qualification and a deeper understanding of how existing regulatory safety pathways address this emerging class of non-intoxicating ingredients. Anchor panelist: Alleh Lindquist, Co-Founder & CEO of FloraWorks, whose company built an audit-ready cannabinoid ingredient (TruCBN™) backed by a 1,020-participant randomized controlled trial, a completed GLP toxicology and genotoxicity package, and a GRAS process nearing completion.